Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
about
Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not usefulPharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study.Ethanol lock therapy: a pilot infusion study in infants.Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study.
P2860
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@ast
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@en
type
label
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@ast
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@en
prefLabel
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@ast
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@en
P2093
P2860
P356
P1476
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
@en
P2093
Camilla Buöen
Mikael S Thomsen
Sture Holm
P2860
P304
P356
10.1177/0091270003252243
P577
2003-05-01T00:00:00Z